BofA analyst Allen Lutz lowered the firm’s price target on Owens & Minor to $4.70 from $7.50 and keeps an Underperform rating on the shares. The firm, which expects O&M to divest its Product and Healthcare Services hospital distribution business in the near-term, is lowering its FY25 and FY26 revenue estimates to reflect the removal of the P&HS segment from its model starting in Q2 as well as slightly lower growth in Patient Direct.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMI:
- Sell Rating for Owens & Minor Amid Divestiture and Growth Challenges
- Owens & Minor price target lowered to $7 from $11 at Citi
- Owens & Minor Reports Q2 2025 Earnings and Strategic Shift
- Owens & Minor’s Strategic Shift in Earnings Call
- Morning Movers: MeridianLink jumps after pact to be acquired by Centerbridge